Skip to content

Science
Team
Partnering
Contact
News

Menu

Science
Team
Partnering
Contact
News

August 2022

Kurome Therapeutics

Activation Of Targetable Inflammatory Immune Signaling Is Seen In Myelodysplastic Syndromes With SF3B1 Mutations

Research Papers / Caleb Conlin

Activation Of Targetable Inflammatory Immune Signaling Is Seen In Myelodysplastic Syndromes With SF3B1 Mutations Read More »

Search

Recent Posts

Kurome Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for KME-0584 for the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS)
Double trouble: IRAK1/4 inhibitors in AML/MDS
KUROME THERAPEUTICS TARGETS DYSREGULATED IMMUNE SIGNALING IN BLOOD CANCER PATIENTS
Paralog-Specific Signaling By IRAK1/4 Maintains MyD88-Independent Functions In MDS/AML
Activation Of Targetable Inflammatory Immune Signaling Is Seen In Myelodysplastic Syndromes With SF3B1 Mutations

Recent Comments

No comments to show.

Archives

February 2024
September 2023
May 2023
August 2022
July 2022
February 2022
January 2022
October 2021
February 2021
January 2021
April 2020
September 2019
August 2019
October 2018
December 2015
October 2014
April 2014
July 2013

Categories

News Articles
Presentations
Press Release
Research Papers

Science
Team
Partnering
News
Contact Us

Science
Team
Partnering
News
Contact Us

Accessibility | Privacy | Terms

© 2023 Kurome® Therapeutics. All rights reserved.
Kurome is a registered trademark of Kurome Therapeutics. All rights reserved.